Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy

European Journal of Pharmacology

Volumn 581, Issue 1-2, 2008, Pages 121-131

  Veeraveedu, Punniyakoti T ^a   Watanabe, Kenichi ^a   Ma, Meilei ^a   Palaniyandi, Suresh S ^a,c   Yamaguchi, Ken'ichi ^b   Suzuki, Kenji ^b   Kodama, Makoto ^b   Aizawa, Yoshifusa ^b  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aldosterone; Experimental autoimmune myocarditis; Fibrosis; Remodeling; Torasemide

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); DIURETIC AGENT; LONG ACTING DRUG; MYOSIN; POTASSIUM; SODIUM; TORASEMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE COURSE; DIURESIS; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HEART HEMODYNAMICS; HEART MUSCLE FIBROSIS; IMMUNIZATION; MALE; MUSCLE CELL; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SARCOPLASMIC RETICULUM; URINARY EXCRETION;

ANIMALS; ATRIAL NATRIURETIC FACTOR; BODY WEIGHT; CARDIOMYOPATHY, DILATED; COLLAGEN TYPE III; DISEASE PROGRESSION; DIURETICS; HEART FAILURE; MALE; MATRIX METALLOPROTEINASE 9; MYOCARDITIS; MYOCARDIUM; RATS; RATS, INBRED LEW; RNA, MESSENGER; SULFONAMIDES; TRANSFORMING GROWTH FACTOR BETA1; VENTRICULAR FUNCTION, LEFT;

EID: 38949112839     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.11.034     Document Type: Article

References (50)

1. Boesken W.H., and Kult J. High-dose torasemide, given once daily intravenously for one week, in patients with advanced chronic renal failure. Clin. Nephrol. 48 (1997) 22-28
2. Cooper Jr. L.T. Pathology of human myocarditis. In: Cooper Jr. L.T. (Ed). Myocarditis - from Bench to Bedside (2003), Humana press, New Jersey, NJ 358
3. Cory C.R., McCutcheon L.J., O'Grady M., Pang A.W., Geiger J.D., and O'Brien P.J. Compensatory down regulation of myocardial Ca channel in SR from dogs with heart failure. Am. J. Physiol. 264 (1993) H926-H937
4. Cosin J., Diez J., and TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur. J. Heart Fail. 4 (2002) 507-513
5. Delcayre C., and Swynghedauw B. Molecular mechanisms of myocardial remodeling: the role of aldosterone. J. Mol. Cell. Cardiol. 34 (2002) 1577-1584
6. Falcao L.M., Pinto F., Ravara L., and van Zwieten P.A. BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction. J. Renin-Angiotensin-Aldosterone Syst. 5 (2004) 121-129
7. Fortuno A., Muniz P., Ravassa S., Rodriguez J.A., Fortuno M.A., Zalba G., and Diez J. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension 34 (1999) 138-143
8. Ghys A., Denef J., de Suray J.M., Gerin M., Georges A., Delarge J., and Willems J. Pharmacological properties of the new potent diuretic torasemide in rats and dogs. Arzneimittelforschung 35 (1985) 1520-1526
9. Ghys A., Denef J., Delarge J., and Georges A. Renal effects of the high ceiling diuretic torasemide in rats and dogs. Arzneimittelforschung 35 (1985) 1527-1531
10. Gonzalez A., Lopez B., Querejeta R., and Diez J. Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease?. J. Mol. Cell. Cardiol. 34 (2002) 1585-1593
11. Goodfriend T.L., Ball D.L., Oelkers W., and Bahr V. Torsemide inhibits aldosterone secretion in vitro. Life Sci. 63 (1998) PL45-PL50
12. Greger R. Inhibition of active NaCl reabsorption in the thick ascending limb of the loop of Henle by torasemide. Arzneimittelforschung 38 (1988) 151-152
13. Kasama S., Toyama T., Hatori T., Sumino H., Kumakura H., Takayama Y., Ichikawa S., Suzuki T., and Kurabayashi M. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure. Heart 92 (2006) 1434-1440
14. Kodama M., Matsumoto Y., Fujiwara M., Masani F., Izumi T., and Shibata A. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin. Immunol. Immunopathol. 57 (1990) 250-262
15. Kodama M., Hanawa H., Saeki M., Hosono H., Inomata T., Suzuki K., and Shibata A. Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ. Res. 75 (1994) 278-284
16. Laurent G.J. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am. J. Physiol. 252 (1987) C1-C9
17. Liguori A., Casini A., Di Loreto M., Andreini I., and Napoli C. Loop diuretics enhance the secretion of prostacyclin in vitro, in healthy persons, and in patients with chronic heart failure. Eur. J. Clin. Pharmacol. 55 (1999) 117-124
18. Linck B., Boknik P., Eschenhagen T., Muller F.U., Neumann J., Nose M., Jones L.R., Schmitz W., and Scholz H. Messenger RNA expression and immunological quantification of phospholamban and SR-Ca (2+)-ATPase in failing and nonfailing human hearts. Cardiovasc. Res. 31 (1996) 625-632
19. Lopez B., Querejeta R., Gonzalez A., Sanchez E., Larman M., and Diez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J. Am. Coll. Cardiol. 43 (2004) 2028-2035
20. Mizuno Y., Yoshimura M., Yasue H., Sakamoto T., Ogawa H., Kugiyama K., Harada E., Nakayama M., Nakamura S., Ito T., Shimasaki Y., Saito Y., and Nakao K. Aldosterone production is activated in failing ventricle in humans. Circulation 103 (2001) 72-77
21. Morgan J.P., Erny R.E., Allen P.D., Grossman W., and Gwathmey J.K. Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure. Circulation 81 2 Suppl (1990) III-21-III-32
22. Muniz P., Fortuno A., Zalba G., Fortuno M.A., and Diez J. Effects of loop diuretics on angiotensin II-stimulated vascular smooth muscle cell growth. Nephrol. Dial. Transplant. 16 Suppl 1 (2001) 14-17
23. Murray M.D., Deer M.M., Ferguson J.A., Dexter P.R., Bennett S.J., Perkins S.M., Smith F.E., Lane K.A., Adams L.D., Tierney W.M., and Brater D.C. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am. J. Med. 111 (2001) 513-520
24. Patterson J.H., Adams Jr. K.F., Applefeld M.M., Corder C.N., and Masse B.R. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy 14 (1994) 514-521
25. Rihal C.S., Nishimura R.A., Hatle L.K., Bailey K.R., and Tajik A.J. Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy. Relation to symptoms and prognosis. Circulation 90 (1994) 2772-2779
26. Rutschow S., Li J., Schultheiss H.P., and Pauschinger M. Myocardial proteases and matrix remodeling in inflammatory heart disease. Cardiovasc. Res. 69 (2006) 646-656
27. Satoh M., Nakamura M., Saitoh H., Satoh H., Akatsu T., Iwasaka J., Masuda T., and Hiramori K. Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. Clin. Sci. (Lond) 102 (2002) 381-386
28. Shinyama H., Yamanaga K., Akira T., Uchida T., Yaguchi M., Watanabe M., and Kagitani Y. Effects of single and repeated administration of torasemide on plasma renin activity and aldosterone concentration in rats. Clin. Rep. (Kiso to Rinso) 30 (1996) 503-510
29. Silberbach M., and Roberts Jr. C.T. Natriuretic peptide signalling: molecular and cellular pathways to growth regulation. Cell. Signal. 13 (2001) 221-231
30. Silvestre J.S., Robert V., Heymes C., Aupetit-Faisant B., Mouas C., Moalic J.M., Swynghedauw B., and Delcayre C. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J. Biol. Chem. 273 (1998) 4883-4891
31. Silvestre J.S., Heymes C., Oubenaissa A., Robert V., Aupetit-Faisant B., Carayon A., Swynghedauw B., and Delcayre C. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 99 (1999) 2694-2701
32. Spannheimer A., Goertz A., and Dreckmann-Behrendt B. Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint. Int. J. Clin. Pract. 52 (1998) 467-471
33. Tsutamoto T., Sakai H., Wada A., Ishikawa C., Ohno K., Fujii M., Yamamoto T., Takayama T., Dohke T., and Horie M. Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure. J. Am. Coll. Cardiol. 44 (2004) 2252-2253
34. Uchida T., Hayashi K., Suzuki Y., and Matsumura Y. Effects of torasemide on renal haemodynamics and function in anaesthetized dogs. Clin. Exp. Pharmacol. Physiol. 18 (1991) 497-504
35. Uchida T., Ohtaki Y., Kido H., and Watanabe M. Diuretic profile of a novel loop diuretic torasemide in rats and dogs. Drugs Exp. Clin. Res. 17 (1991) 293-298
36. Uchida T., Yamanaga K., Nishikawa M., Ohtaki Y., Kido H., and Watanabe M. Anti-aldosteronergic effect of torasemide. Eur. J. Pharmacol. 205 (1991) 145-150
37. Uchida T., Yamanaga K., Kido H., Ohtaki Y., and Watanabe M. Diuretic and vasodilating actions of torasemide. Cardiology 84 Suppl 2 (1994) 14-17
38. Uechi M., Matsuoka M., Kuwajima E., Kaneko T., Yamashita K., Fukushima U., and Ishikawa Y. The effects of the loop diuretics furosemide and torasemide on diuresis in dogs and cats. J. Vet. Med. Sci. 65 (2003) 1057-1061
39. van Zwieten P.A. Comparative mechanisms of action of diuretic drugs in hypertension. Eur. Heart J. 13 (1992) 2-4 Suppl G
40. Vetter R., Rehfeld U., Reissfelder C., Weiss W., Wagner K.D., Gunther J., Hammes A., Tschope C., Dillmann W., and Paul M. Transgenic overexpression of the sarcoplasmic reticulum Ca2+ATPase improves reticular Ca2+ handling in normal and diabetic rat hearts. FASEB J. 16 (2002) 1657-1659
41. Watanabe K., Ohta Y., Nakazawa M., Higuchi H., Hasegawa G., Naito M., Fuse K., Ito M., Hirono S., Tanabe N., Hanawa H., Kato K., Kodama M., and Aizawa Y. Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. Br. J. Pharmacol. 130 (2000) 1489-1495
42. Weber K.T., and Brilla C.G. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83 (1991) 1849-1865
43. Weber K.T., and Eghbali M. Collagen matrix synthesis and degradation in the development and regression of left ventricular hypertrophy. Cardiovasc. Rev. Rep. 12 (1991) 61-69
44. Weber K.T., Brilla C.G., and Janicki J.S. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc. Res. 27 (1993) 341-348
45. Weber K.T., Gerling I.C., Kiani M.F., Guntaka R.V., Sun Y., Ahokas R.A., Postlethwaite A.E., and Warrington K.J. Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. Curr. Drug Targets 4 (2003) 505-516
46. Wittner M., Di Stefano A., Schlatter E., Delarge J., and Greger R. Torasemide inhibits NaCl reabsorption in the thick ascending limb of the loop of Henle. Pflugers Arch. 407 (1986) 611-614
47. Wittner M., Di Stefano A., Wangemann P., Delarge J., Liegeois J.F., and Greger R. Related analogues of torasemide - structure function relationships - experiments in the thick ascending limb of the loop of Henle of rabbit nephron. Pflugers Arch. 408 (1987) 54-62
48. Yamaguchi K. Effects of water deprivation on immunoreactive angiotensin II levels in plasma, cerebroventricular perfusate and hypothalamus of the rat. Acta Endocrinol (Copenh) 97 (1981) 137-144
49. Yamato M., Sasaki T., Honda K., Fukuda M., Akutagawa O., Okamoto M., and Hayashi T. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ. J. 67 (2003) 384-390
50. Yndestad A., Ueland T., Oie E., Florholmen G., Halvorsen B., Attramadal H., Simonsen S., Froland S.S., Gullestad L., Christensen G., Damas J.K., and Aukrust P. Elevated levels of activin A in heart failure: potential role in myocardial remodeling. Circulation 109 (2004) 1379-1385